164 related articles for article (PubMed ID: 12568645)
1. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
2. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
3. Orphan anticancer drug rejected.
Burton A
Lancet Oncol; 2003 Sep; 4(9):524. PubMed ID: 12965283
[No Abstract] [Full Text] [Related]
4. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
5. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Ryan DP; Puchalski T; Supko JG; Harmon D; Maki R; Garcia-Carbonero R; Kuhlman C; Winkelman J; Merriam P; Quigley T; Jimeno J; Manola J; Demetri GD
Oncologist; 2002; 7(6):531-8. PubMed ID: 12490740
[TBL] [Abstract][Full Text] [Related]
6. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B.
Cuevas C; Pérez M; Martín MJ; Chicharro JL; Fernández-Rivas C; Flores M; Francesch A; Gallego P; Zarzuelo M; de La Calle F; García J; Polanco C; Rodríguez I; Manzanares I
Org Lett; 2000 Aug; 2(16):2545-8. PubMed ID: 10956543
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek FJ; Broggini M; Faircloth GT; D'Incalci M
Eur J Cancer; 2005 Jan; 41(2):323-33. PubMed ID: 15661559
[TBL] [Abstract][Full Text] [Related]
10. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
[TBL] [Abstract][Full Text] [Related]
11. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
García-Nieto R; Manzanares I; Cuevas C; Gago F
J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
[No Abstract] [Full Text] [Related]
12. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
[TBL] [Abstract][Full Text] [Related]
13. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
14. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Laverdiere C; Kolb EA; Supko JG; Gorlick R; Meyers PA; Maki RG; Wexler L; Demetri GD; Healey JH; Huvos AG; Goorin AM; Bagatell R; Ruiz-Casado A; Guzman C; Jimeno J; Harmon D
Cancer; 2003 Aug; 98(4):832-40. PubMed ID: 12910529
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.
Martinez EJ; Corey EJ
Org Lett; 1999 Jul; 1(1):75-7. PubMed ID: 10822537
[TBL] [Abstract][Full Text] [Related]
17. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R; Supko JG; Maki RG; Manola J; Ryan DP; Harmon D; Puchalski TA; Goss G; Seiden MV; Waxman A; Quigley MT; Lopez T; Sancho MA; Jimeno J; Guzman C; Demetri GD
J Clin Oncol; 2005 Aug; 23(24):5484-92. PubMed ID: 16110008
[TBL] [Abstract][Full Text] [Related]
18. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
19. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
20. Transcription of the multidrug resistance gene MDR1: a therapeutic target.
Scotto KW; Johnson RA
Mol Interv; 2001 Jun; 1(2):117-25. PubMed ID: 14993331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
